Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dyslipidemias | 2 | 2023 | 234 | 1.360 |
Why?
|
| Endocrine System Diseases | 1 | 2025 | 43 | 0.940 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2025 | 171 | 0.820 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2023 | 84 | 0.800 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 1958 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2025 | 819 | 0.740 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 178 | 0.730 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 732 | 0.650 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 38 | 0.500 |
Why?
|
| Atherosclerosis | 1 | 2023 | 920 | 0.470 |
Why?
|
| Autoantibodies | 1 | 2016 | 436 | 0.410 |
Why?
|
| Diet | 1 | 2013 | 1140 | 0.260 |
Why?
|
| Hypertriglyceridemia | 1 | 2025 | 104 | 0.220 |
Why?
|
| Emergencies | 1 | 2025 | 171 | 0.220 |
Why?
|
| Adolescent | 6 | 2025 | 19351 | 0.210 |
Why?
|
| Human Growth Hormone | 1 | 2011 | 74 | 0.180 |
Why?
|
| Hypolipidemic Agents | 1 | 2023 | 181 | 0.180 |
Why?
|
| Dwarfism | 1 | 2011 | 98 | 0.180 |
Why?
|
| Growth Disorders | 1 | 2011 | 209 | 0.170 |
Why?
|
| Child | 6 | 2025 | 24384 | 0.170 |
Why?
|
| Risk Factors | 3 | 2023 | 10284 | 0.160 |
Why?
|
| Zinc Transporter 8 | 1 | 2016 | 6 | 0.130 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Antibody Specificity | 1 | 2016 | 204 | 0.120 |
Why?
|
| C-Peptide | 1 | 2016 | 113 | 0.120 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 93 | 0.120 |
Why?
|
| Humans | 10 | 2025 | 125086 | 0.120 |
Why?
|
| Epitopes | 1 | 2016 | 434 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2023 | 3456 | 0.110 |
Why?
|
| Adult | 2 | 2023 | 29632 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2025 | 8202 | 0.100 |
Why?
|
| Life Style | 1 | 2005 | 415 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2005 | 675 | 0.090 |
Why?
|
| United States | 2 | 2023 | 10912 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2025 | 14005 | 0.060 |
Why?
|
| Pancreatitis | 1 | 2025 | 132 | 0.050 |
Why?
|
| Male | 4 | 2025 | 61463 | 0.050 |
Why?
|
| Female | 4 | 2025 | 66747 | 0.050 |
Why?
|
| Infant | 1 | 2016 | 12476 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 41 | 0.030 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.030 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 75 | 0.030 |
Why?
|
| Diet, Mediterranean | 1 | 2005 | 12 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 82 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 190 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2005 | 115 | 0.030 |
Why?
|
| Language | 1 | 2016 | 198 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2005 | 70 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 144 | 0.030 |
Why?
|
| Diuretics | 1 | 2005 | 171 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2005 | 779 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 228 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 224 | 0.030 |
Why?
|
| Aspirin | 1 | 2005 | 222 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 244 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 423 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 570 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 433 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1169 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1098 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 606 | 0.020 |
Why?
|
| Exercise | 1 | 2005 | 812 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2016 | 826 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 2247 | 0.010 |
Why?
|